Skip to content

Long-limb or Distal Gastric Bypass for Superobesity - Randomized Study

Long -Limb Gastric or Distal Gastric Bypass in the Treatment of Super Obese Patients - a Prospective Randomized Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00821197
Enrollment
115
Registered
2009-01-13
Start date
2011-02-28
Completion date
2025-05-31
Last updated
2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, laparoscopy, bariatric, super obesity

Brief summary

The main study objective: To evaluate long-limb gastric bypass (150 cm alimentary limb) vs. distal gastric bypass (common channel 150 cm) in the treatment of superobesity (BMI 50-60 kg/m2). The main study hypothesis: Distal bypass accomplish an estimated 10-20 % larger weightloss than long-limb gastric bypass 1 year after surgery. Patients subject to distal bypass have more gastrointestinal side effects and more extensive nutritional deficiences compared to long-limb gastric bypass.

Detailed description

Technical data will later be published in detail

Interventions

PROCEDURElong-limb gastric bypass

Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)

Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)

Sponsors

The Hospital of Vestfold
CollaboratorOTHER
Oslo University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* BMI 50 - 60 kg/m2 at admission for evaluation for bariatric surgery * BMI 48 - 62 kg/m2 at study inclusion * informed consent * scheduled for bariatric surgery

Exclusion criteria

* previous bariatric surgery * previous major abdominal surgery * previous history or established urolithiasis * viral hepatitis, liver cirrhosis of any kind * factors making the patient not eligible to understand and commit to the study protocol (severe psychiatric disease or drug/narcotic abuse)

Design outcomes

Primary

MeasureTime frameDescription
Primary outcome: weight loss2 years postoperativelyphysical examination

Secondary

MeasureTime frameDescription
Adverse events2 years postoperativemedical history, journals
Number of patients with vitamin deficiencies2 years postoperativeBlood samples
Number of patients with mineral deficiencies2 years postoperativeBlood samples
Number of participants with malnutrition2 years postoperativeBlood samples
Secondary outcome: Quality of life2 years postoperativequestionnaire
Health related Quality of life5 years postoperativequestionnaire
Number of patients with malnutrition5 years postoperativeBlood samples
Weight loss 10 years10 years postoperativeWeight measure
Weight loss 5 year5 year postoperativephysical examination

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026